Cardiovascular Event Reductions and Lipid Remodeling Metrics following Early Initiation of PCSK9 Inhibitors in Post-Myocardial Infarction Patients

International Journal of Medicine and Medical Sciences | Vol. 16, No. 8, August 2026 | pp. 89–96

DOI: 10.46882/2026/IJMMS/160089

Original Research Article

Cardiovascular Event Reductions and Lipid Remodeling Metrics following Early Initiation of PCSK9 Inhibitors in Post-Myocardial Infarction Patients

Emily R. Bellingham¹, Arthur G. Pendelton², Ian K. Macallister³*

¹Nuffield Department of Medicine, John Radcliffe Hospital, University of Oxford, Oxford, UK.

²Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.

³Department of Medicine, McGill University Health Centre, Montreal, QC, Canada.

Abstract:

Achieving ultra-low low-density lipoprotein cholesterol (LDL-C) targets rapidly after an acute coronary syndrome is critical to stabilize vulnerable atheromatous plaques and mitigate early recurrent cardiovascular event risk. This prospective, randomized, double-blind, active-controlled trial evaluated the efficacy, safety, and vascular remodeling parameters of early evolocumab initiation (a PCSK9 inhibitor) combined with high-intensity statin therapy versus statin monotherapy. We evaluated 150 adult patients hospitalized with an acute myocardial infarction who presented with a baseline LDL-C ≥ 1.8 mmol/L despite background statin intake. Participants were randomized 1:1 within 72 hours of percutaneous coronary intervention to receive either subcutaneous evolocumab (140 mg every 2 weeks, n = 75) or a matching placebo (n = 75), alongside daily atorvastatin (80 mg) for 12 months. At 12 months, the evolocumab combination arm achieved a profound 74.5% reduction in mean LDL-C, collapsing from 2.45 ± 0.42 mmol/L to an absolute nadir of 0.62 ± 0.11 mmol/L (p < 0.001). The control group fell to 1.42 ± 0.28 mmol/L. Recurrent major adverse cardiovascular events (MACE) occurred in 4.0% of the evolocumab group compared to 12.0% in the monotherapy arm (p < 0.05). High-resolution intravascular ultrasound imaging confirmed significant plaque regression and an increase in fibrous cap thickness (+21.4 ± 3.5 μm, p < 0.01) favoring early combination intervention. Early initialization of PCSK9 inhibitors drives exceptional LDL-C clearance and directly modifies plaque structural geometry, offering superior secondary prevention post-infarction.

Keywords: Myocardial Infarction, PCSK9 Inhibitor, Evolocumab, Lipid Remodeling, Low-Density Lipoprotein, Plaque Regression

Manuscript Timeline: Received: May 15, 2026; Revised: June 20, 2026; Accepted: July 12, 2026; Published: August 18, 2026.

Citation: Bellingham ER, Pendelton AG, Macallister IK. Cardiovascular Event Reductions and Lipid Remodeling Metrics following Early Initiation of PCSK9 Inhibitors in Post-Myocardial Infarction Patients. International Journal of Medicine and Medical Sciences, 2026, 16(8): 89–96. DOI: 10.46882/2026/IJMMS/160089

Subscribe to read the full article: https://internationalscholarsjournals.org/subscribe-to-read